Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2191 to 2205 of 8900 results

  1. Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779) [ID6326]

    In development Reference number: GID-TA11764 Expected publication date:  23 July 2026

  2. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update): draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 23 February 2026.

  3. Prognostic tests for multiple myeloma

    Awaiting development Reference number: GID-HTG10153 Expected publication date: TBC

  4. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)

    In development Reference number: GID-NG10216 Expected publication date:  15 July 2026

  5. Lifileucel for previously treated unresectable or metastatic melanoma ID3863

    In development Reference number: GID-TA10752 Expected publication date:  10 July 2026

  6. Sotatercept for treating pulmonary arterial hypertension [ID6163]

    In development Reference number: GID-TA11103 Expected publication date: TBC

  7. Capsule sponge tests for detection of Barrett's oesophagus and oesophageal cancer (provisional title)

    In development Reference number: GID-HTE10070 Expected publication date: TBC

  8. Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]

    In development Reference number: GID-TA11572 Expected publication date:  21 May 2026

  9. AHEAD implants for external ear prosthesis

    Topic prioritisation

  10. Intradiscal oxygen-ozone treatment of symptomatic lumbar disc herniation

    Topic prioritisation

  11. Insertion of Stoma Preservation Device

    Topic prioritisation

  12. Botulinum Toxin injection prior to Abdominal wall reconstruction

    Topic prioritisation

  13. Olorofim for treating invasive fungal infections in people 16 years and over [TSID11983]

    Topic prioritisation

  14. Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years [TSID12002]

    Topic prioritisation

  15. Secukinumab biosimilar for treating plaque psoriasis [TSID11992]

    Topic prioritisation